1. CpG oligonucleotides partially inhibit growth of Mycobacterium tuberculosis, but not Salmonella or Listeria, in human monocyte-derived macrophages.
- Author
-
Wang JP, Hayashi T, Datta SK, Kornbluth RS, Raz E, and Guiney DG
- Subjects
- Animals, Antitubercular Agents chemistry, Base Sequence, Humans, Immunity, Innate drug effects, In Vitro Techniques, Interferon-gamma pharmacology, Listeria monocytogenes growth & development, Listeria monocytogenes immunology, Listeria monocytogenes pathogenicity, Macrophages microbiology, Mice, Monocytes drug effects, Monocytes immunology, Monocytes microbiology, Mycobacterium tuberculosis growth & development, Mycobacterium tuberculosis immunology, Mycobacterium tuberculosis pathogenicity, Oligodeoxyribonucleotides genetics, Recombinant Proteins, Salmonella enterica growth & development, Salmonella enterica immunology, Salmonella enterica pathogenicity, Species Specificity, Virulence, Antitubercular Agents pharmacology, Listeria monocytogenes drug effects, Macrophages drug effects, Macrophages immunology, Mycobacterium tuberculosis drug effects, Oligodeoxyribonucleotides pharmacology, Salmonella enterica drug effects
- Abstract
Immunostimulatory DNA sequences and their synthetic oligonucleotide analogs (CpG-ODN) activate innate immunity and can stimulate antibacterial effects against numerous intracellular pathogens. While it has been shown previously that CpG-ODN inhibit growth of Mycobacterium avium in murine and human macrophages, we now report that Mycobacterium tuberculosis growth can be inhibited by CpG-ODN treatment of human monocyte-derived macrophages (hMDM). This inhibitory effect was reversed by IFN-gamma, which has been shown repeatedly to enhance the growth of virulent M. tuberculosis in cultured hMDM. The antibacterial effect of CpG-ODN in human macrophages was specific for M. tuberculosis when compared to other intracellular pathogens including Listeria monocytogenes and Salmonella enterica serovar Dublin. These data indicate that CpG-ODN can improve the ability of hMDM to contain growth of virulent M. tuberculosis.
- Published
- 2005
- Full Text
- View/download PDF